This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
TMO Stock Set to Gain From the Launch of New Narcotic Analyzers
by Zacks Equity Research
Thermo Fisher launches new TruNarc analyzers to help law enforcement quickly detect 1,200+ substances, boosting field safety and drug interdiction efforts.
Insulet Gains 78.5% in a Year: What's Driving the Stock?
by Zacks Equity Research
PODD's shares rise on the back of Omnipod 5's growth, global expansion, and strong Q1 2025 gains despite rising operating costs and macro headwinds.
Should You Retain Henry Schein Stock in Your Portfolio Right Now?
by Zacks Equity Research
Investors are optimistic about HSIC, owing to the strong performance of its Henry Schein One business.
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock
by Zacks Equity Research
EW's new late-breaking clinical data shows early intervention in AS may slash significant costs and improve patient outcomes.
Penumbra Rallies 35.9% in a Year: What's Driving the Stock?
by Zacks Equity Research
PEN has shown notable strength over the past year, driven by the performance of its core U.S. thrombectomy business. Solid international prospects instill optimism.
Should Tandem Diabetes Stock Stay in Your Portfolio Now?
by Zacks Equity Research
Investors remain optimistic about TNDM, courtesy of its strong t:slim X2 performance and breakthrough innovations.
AST Business Growth & Strategic Acquisitions Support STERIS Stock
by Zacks Equity Research
STE frequently engages in strategic acquisitions and joint ventures to optimize its portfolio of businesses.
What's Driving Quest Diagnostics Stock's 25.6% Rally in a Year?
by Zacks Equity Research
DGX has shown notable strength in the past year, driven by robust core performance and contributions from acquisitions.
Should You Continue to Hold Charles River Stock in Your Portfolio?
by Zacks Equity Research
CRL stays on investors' radars due to the strength of partnerships and segmental prospects.
Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software
by Zacks Equity Research
ILMN's latest software features easy-to-use oncology apps, enhanced multiomics pipelines and AWS F2 support, enabling faster turnaround times.
PBH vs. ESLOY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PBH vs. ESLOY: Which Stock Is the Better Value Option?
Prestige Consumer Stock Up 8% Since Q4 Earnings Beat, Margin Increase
by Zacks Equity Research
PBH experiences steady international growth in the fourth quarter, banking on strong sales of the Hydralyte brand.
Prestige Consumer Healthcare (PBH) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Prestige Consumer Healthcare (PBH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Prestige Consumer Healthcare (PBH) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of 1.54% and 2.62%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Insights Into Prestige Consumer Healthcare (PBH) Q4: Wall Street Projections for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Prestige Consumer Healthcare (PBH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Prestige Consumer Healthcare (PBH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GE HealthCare Technologies (GEHC) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
GE HealthCare (GEHC) delivered earnings and revenue surprises of 10.99% and 2.57%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
EMEA Growth & Product Launches to Support Boston Scientific Stock
by Zacks Equity Research
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
PBH or ABT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. ABT: Which Stock Is the Better Value Option?
3 Undervalued Medical Device Stocks to Buy in 2025 Amid Tariff Woes
by Harshit Gupta
Here, we discuss three medical device stocks ,COR, HIMS and PBH, that offer cheap valuations, making them attractive bets amid tariff risks.
PBH vs. SYK: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBH vs. SYK: Which Stock Is the Better Value Option?
Prestige Consumer Gains 17.1% in a Year: What's Driving the Stock?
by Zacks Equity Research
PBH's shares rise on the back of its portfolio of consumer brands and focus on core strategies to achieve long-term success.
Should You Consider Retaining PBH Stock in Your Portfolio Now?
by Zacks Equity Research
Investors remain optimistic about Prestige Consumer due to its strong focus on brand building and strategic acquisition.
PBH or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. BSX: Which Stock Is the Better Value Option?
PBH Q3 Earnings Beat Estimates, EPS View Raised, Shares Gain 14.8%
by Zacks Equity Research
Prestige Consumer Healthcare witnesses continued international growth in the third quarter, banking on strong sales of the Hydralyte brand.